Collegium Pharmaceutical
COLL
229 hedge funds and large institutions have $1.28B invested in Collegium Pharmaceutical in 2024 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 93 increasing their positions, 75 reducing their positions, and 34 closing their positions.
240% more call options, than puts
Call options by funds: $2.04M | Put options by funds: $599K
24% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 75
9% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 34
0% more funds holding
Funds holding: 228 → 229 (+1)
2.92% less ownership
Funds ownership: 124.05% → 121.14% (-2.9%)
17% less capital invested
Capital invested by funds: $1.54B → $1.28B (-$262M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$28.5M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$17.3M |
| 3 |
JFG
Jefferies Financial Group
New York
|
+$10.8M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$10.1M |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$7.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$33.1M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$21.8M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$19.1M |
| 4 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
-$9.53M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$8.47M |
COLL Hedge Fund Activity: Q2 2024 in Review
229 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q2 2024, worth a combined $1.28B — down 17% from $1.54B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new COLL positions and 34 closed out — a net gain of 3 holders — while 93 added to existing stakes and 75 trimmed.
The largest buyer was Pacer Advisors, adding an estimated $28.5M. The largest seller was Camber Capital Management, exiting entirely with an estimated $33.1M sold.
- 229 institutional investors held Collegium Pharmaceutical (COLL) as of Q2 2024, up from 228 in Q1 2024.
- Funds reported $1.28B of Collegium Pharmaceutical stock for Q2 2024, down 17% quarter-over-quarter.
- 37 funds opened new Collegium Pharmaceutical positions in Q2 2024 and 34 closed out, a net change of +3 holders.
- The largest Collegium Pharmaceutical buyer in Q2 2024 was Pacer Advisors, an estimated $28.5M added.
- The largest Collegium Pharmaceutical seller in Q2 2024 was Camber Capital Management, an estimated $33.1M sold.
Based on aggregated 13F filings for Q2 2024.